Effective January 1st, Genentech will be updating the co-pay program benefit period. The program will be moving from a 12-month benefit to a calendar year benefit (January to December).
Patient benefit will automatically renew annually for all patients enrolled in the program on January 1st.
For more information, please call the Help Desk at 800-636-0373.
The information contained in this section of the site is intended for US specialty pharmacy representatives only. Click "OK" if you are a specialty pharmacy representative.
With the ENSPRYNG Co-pay Program, eligible, commercially insured patients pay as little as $5 per 30-day supply of ENSPRYNG. The program covers the rest of the patient's out-of-pocket costs, up to $20,000 in assistance per 12-month period.
There are no income requirements for the ENSPRYNG Co-pay Program.
If a patient is not eligible for the ENSPRYNG Co-pay Program, there may be other options for financial assistance. Call (844) NSPRYNG (844-677-7964) or visit Genentech-Access.com/ENSPRYNG to learn more.
ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
ENSPRYNG is contraindicated in patients with a known hypersensitivity to satralizumab or any of the inactive ingredients, an active hepatitis B infection, or active or untreated latent tuberculosis.
Delay ENSPRYNG administration in patients with an active infection until the infection is resolved. Vaccination with live or live attenuated vaccines is not recommended during treatment.
Elevated Liver Enzymes
Monitor ALT and AST levels during treatment; interruption of ENSPRYNG may be required.
Decreased Neutrophil Counts
Monitor neutrophils during treatment.
The most common adverse reactions (≥15% in either trial) were nasopharyngitis (31%), headache (27%), upper respiratory tract infection (19%), rash (17%), arthralgia (17%), extremity pain (15%), gastritis (15%), fatigue (15%), and nausea (15%).